Candel Therapeutics (CADL) News Today $3.98 -0.01 (-0.25%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Q4 Earnings Forecast for CADL Issued By HC WainwrightNovember 21 at 2:13 AM | americanbankingnews.comFY2024 Earnings Forecast for CADL Issued By HC WainwrightCandel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Equities research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for Candel Therapeutics in a research report issued on Monday, November 18th. HC Wainwright analyst V. Bernardino now anticipates that the companyNovember 20 at 6:39 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL)November 20 at 1:55 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for CADL Q4 Earnings?Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Candel Therapeutics in a report released on Monday, November 18th. HC Wainwright analyst V. Bernardino expects that the company will earn ($0.30) per share for tNovember 19 at 6:36 AM | marketbeat.comCandel Therapeutics Advances in Cancer Trials Amid Financial ChallengesNovember 19 at 3:48 AM | markets.businessinsider.comPromising Potential of Candel Therapeutics’ CAN-2409 Drives Buy RatingNovember 18 at 5:45 PM | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Candel Therapeutics (NASDAQ:CADL)HC Wainwright reiterated a "buy" rating and set a $11.00 price objective on shares of Candel Therapeutics in a research note on Monday.November 18 at 8:11 AM | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Short Interest UpdateCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,780,000 shares, an increase of 8.5% from the October 15th total of 1,640,000 shares. Approximately 9.0% of the company's stock are short sold. Based on an average daily volume of 255,200 shares, the short-interest ratio is presently 7.0 days.November 17, 2024 | marketbeat.comCandel Therapeutics reports Q3 EPS (33c) vs. (29c) last yearNovember 14, 2024 | markets.businessinsider.comCandel Therapeutics sees cash runway to end of 1Q25November 14, 2024 | markets.businessinsider.comCandel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps upNovember 14, 2024 | proactiveinvestors.comCandel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMINovember 9, 2024 | proactiveinvestors.comCandel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMINovember 9, 2024 | proactiveinvestors.comCandel Therapeutics to Present at Jefferies London Healthcare Conference 2024November 8, 2024 | markets.businessinsider.comCandel Therapeutics (NASDAQ:CADL) Stock Price Up 2.5% - Time to Buy?Candel Therapeutics (NASDAQ:CADL) Trading 2.5% Higher - What's Next?November 7, 2024 | marketbeat.comCandel Therapeutics to present data at SITC annual meeting on CAN-3110November 6, 2024 | markets.businessinsider.comCandel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical resultsNovember 5, 2024 | proactiveinvestors.comCandel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade GliomaNovember 5, 2024 | globenewswire.comCandel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You ThinkNovember 1, 2024 | seekingalpha.comCandel Therapeutics showcases cancer therapy candidates at IOVCOctober 29, 2024 | markets.businessinsider.comCandel Therapeutics Advances in Cancer Treatment TrialsOctober 29, 2024 | finance.yahoo.comCandel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)October 28, 2024 | finance.yahoo.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells 15,000 Shares of StockOctober 16, 2024 | insidertrades.comCandel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 SharesCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the business's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $6.02, for a total transaction of $90,300.00. Following the completion of the transaction, the insider now directly owns 929,873 shares in the company, valued at $5,597,835.46. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.October 15, 2024 | marketbeat.comCandel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual MeetingOctober 4, 2024 | globenewswire.comCandel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 SharesOctober 4, 2024 | insidertrades.comSands Capital Ventures LLC Cuts Position in Candel Therapeutics, Inc. (NASDAQ:CADL)Sands Capital Ventures LLC reduced its holdings in shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 50.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 405,837 shares of the company's stockSeptember 21, 2024 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%September 13, 2024 | finance.yahoo.comCandel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comCandel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 10.1% in AugustCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,630,000 shares, an increase of 10.1% from the July 31st total of 1,480,000 shares. Based on an average trading volume of 537,500 shares, the days-to-cover ratio is currently 3.0 days. Approximately 8.9% of the company's stock are sold short.September 1, 2024 | marketbeat.comCADL Sep 2024 9.000 call (CADL240920C00009000)August 30, 2024 | finance.yahoo.comCandel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 5.7% in JulyCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 1,480,000 shares, a growth of 5.7% from the July 15th total of 1,400,000 shares. Based on an average daily volume of 650,800 shares, the days-to-cover ratio is currently 2.3 days. Currently, 8.0% of the shares of the company are sold short.August 18, 2024 | marketbeat.comCandel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 13, 2024 | finance.yahoo.comCharles Schoch Sells 9,884 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) StockJuly 21, 2024 | insidertrades.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 9,884 Shares of StockCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Charles Schoch sold 9,884 shares of the business's stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $6.47, for a total transaction of $63,949.48. Following the transaction, the insider now directly owns 62,520 shares of the company's stock, valued at approximately $404,504.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.July 19, 2024 | marketbeat.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells 13,330 Shares of StockJuly 16, 2024 | insidertrades.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 8,897 Shares of StockJuly 16, 2024 | insidertrades.comCandel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Down 31.6% in JuneCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 1,060,000 shares, a drop of 31.6% from the May 31st total of 1,550,000 shares. Based on an average trading volume of 5,620,000 shares, the short-interest ratio is currently 0.2 days. Approximately 5.6% of the shares of the stock are short sold.June 29, 2024 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Growth in Short InterestCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 1,550,000 shares, a growth of 83.0% from the May 15th total of 846,800 shares. Based on an average trading volume of 5,570,000 shares, the short-interest ratio is currently 0.3 days. Currently, 8.3% of the shares of the company are sold short.June 13, 2024 | marketbeat.comCandel Therapeutics to Join Russell 3000® IndexJune 11, 2024 | globenewswire.comShort Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Drops By 19.4%Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 846,800 shares, a decrease of 19.4% from the April 30th total of 1,050,000 shares. Currently, 5.0% of the shares of the stock are sold short. Based on an average trading volume of 5,450,000 shares, the short-interest ratio is presently 0.2 days.June 1, 2024 | marketbeat.comFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade GliomaMay 30, 2024 | globenewswire.comCandel Reports Upbeat Data From Lung Cancer StudyMay 24, 2024 | markets.businessinsider.comCandel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingMay 23, 2024 | globenewswire.comBiotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024May 23, 2024 | baystreet.caCandel Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | globenewswire.comCandel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingMay 20, 2024 | globenewswire.comCandel Lights Up Investors' Portfolio With 830% GainMay 16, 2024 | markets.businessinsider.comCADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024May 14, 2024 | investorplace.comCandel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 14, 2024 | finance.yahoo.com Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here CADL Media Mentions By Week CADL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼0.460.45▲Average Medical News Sentiment CADL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼172▲CADL Articles Average Week Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LIFE News Today ALGS News Today DRRX News Today URGN News Today GLUE News Today PRTC News Today TERN News Today MREO News Today ARCT News Today YMAB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CADL Stock Alerts